2-甲基-2H-吲唑-4-硼酸频那醇酯 | 885698-95-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 2-甲基-2H-吲唑-4-硼酸频那醇酯
• 英文名称: 2-methyl-2H-indazole-4-boronic acid pinacol ester
• 英文别名: 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole；2-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole；2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole
• CAS: 885698-95-3
• 化学式: C₁₄H₁₉BN₂O₂
• 分子量: 258.128
• InChiKey: YQMBOMPXHDRRIM-UHFFFAOYSA-N

物化性质

• 沸点：
  404.4±18.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.87
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methyl-2H-indazole-4-boronic acid pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methyl-2H-indazole-4-boronic acid pinacol ester
CAS number: 885698-95-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H19BN2O2
Molecular weight: 258.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-2H-吲唑-4-硼酸频那醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.5h， 生成 methyl 3-[[[2,6-difluoro-4-(2-methylindazol-4-yl)phenyl]methylamino]methyl]thiophene-2-carboxylate
  参考文献：
  名称：

  POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1

  摘要：

  描述了肌胆碱受体M1（mAChR M1）的正向变构调节剂，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗神经系统疾病、精神疾病或二者结合的方法。

  公开号：

  US20190330226A1
• 作为产物：
  描述：

  4-溴-1H-吲唑 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.5h， 生成 2-甲基-2H-吲唑-4-硼酸频那醇酯
  参考文献：
  名称：

  [EN] METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS
  [FR] MÉTHODES DE TRAITEMENT DE LA FIBROSE HÉPATIQUE À L'AIDE D'INHIBITEURS DE CALPAIN

  摘要：

  本文披露了通过向需要的受试者施用卡尔佩因抑制剂来治疗肝纤维化的方法。

  公开号：

  WO2020006294A1

文献信息

• [EN] CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF<br/>[FR] MODULATEURS DE CALPAÏNE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：BLADE THERAPEUTICS INC

  公开号：WO2019190885A1

  公开（公告）日：2019-10-03

  Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

  小分子钙蛋白酶调节剂化合物，包括其药用可接受的盐，可以包含在药物组合物中。这些化合物可以通过与主体内的CAPN1、CAPN2和/或CAPN9酶接触来抑制钙蛋白酶，或与钙蛋白酶抑制剂竞争性结合。这些化合物和组合物也可以被用于治疗纤维化疾病或纤维化疾病的继发疾病状态或病情。
• [EN] SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1<br/>[FR] ANALOGUES D'IMIDAZOPYRIDINE ET DE TRIAZOLOPYRIDINE SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR MUSCARINIQUE DE L'ACÉTYLCHOLINE M1
  申请人：UNIV VANDERBILT

  公开号：WO2016172547A1

  公开（公告）日：2016-10-27

  In one aspect, the invention relates to substituted imidazopyridine and triazolopyridine analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代咪唑吡啶和三唑吡啶类似物，它们的衍生物以及相关化合物，这些化合物可用作肌胆碱受体M1（mAChR M1）的正向变构调节剂；制备这些化合物的合成方法；包括这些化合物的药物组合物；以及使用所披露的化合物和组合物治疗与肌胆碱受体功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不旨在限制本发明。
• Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation
  作者：Mingfeng Yu、Theodosia Teo、Yuchao Yang、Manjun Li、Yi Long、Stephen Philip、Benjamin Noll、Gary K. Heinemann、Sarah Diab、Preethi Eldi、Laychiluh Mekonnen、Abel T. Anshabo、Muhammed H. Rahaman、Robert Milne、John D. Hayball、Shudong Wang

  DOI：10.1016/j.ejmech.2021.113248

  日期：2021.3

  cancer drugs are highly sought-after. Herein we detail the discovery of a series of novel pyridine-derived CDK8 inhibitors. Medicinal chemistry optimisation gave rise to 38 (AU1-100), a potent CDK8 inhibitor with oral bioavailability. The compound inhibited the proliferation of MV4-11 acute myeloid leukaemia cells with the kinase activity of cellular CDK8 dampened. No systemic toxicology was observed in

  CDK8通过转录因子的磷酸化或作为四亚基激酶模块的一部分，通过激酶模块与Mediator复合物（一种高度保守的转录共激活因子）的可逆结合来调节转录。已经在各种类型的人类癌症中发现了CDK8的失调，而人们已经理解了CDK8在抑制天然杀伤细胞的抗癌反应中的作用。当前，靶向CDK8的抗癌药物非常受欢迎。本文中，我们详细介绍了一系列新型吡啶衍生的CDK8抑制剂的发现。药物化学优化产生了38（AU1-100），一种具有口服生物利用度的有效CDK8抑制剂。该化合物抑制了MV4-11急性髓性白血病细胞的增殖，同时抑制了细胞CDK8的激酶活性。在用38处理的小鼠中未观察到全身毒理学。这些结果值得对38作为抗癌药进行进一步的临床前研究。
• [EN] POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR D'ACÉTYLCHOLINE MUSCARINIQUE M1
  申请人：UNIV VANDERBILT

  公开号：WO2020086864A1

  公开（公告）日：2020-04-30

  Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.

  描述了甲醇乙酰胆碱受体M1（mAChR M1）的正向变构调节剂，包括这些化合物的药物组合物，并使用这些化合物和组合物治疗神经系统疾病、精神疾病或二者的方法。
• [EN] POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR MUSCARINIQUE DE L'ACÉTYLCHOLINE M1
  申请人：UNIV VANDERBILT

  公开号：WO2017143041A1

  公开（公告）日：2017-08-24

  Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.

  描述了肌胆碱受体M1（mAChR M1）的阳性变构调节剂，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗神经系统疾病、精神疾病或二者结合的方法。